RIDDLE&CODE-GMBH
23.8.2022 10:17:11 CEST | Business Wire | Press release
Riddle&Code GmbH is pleased to announce John Calian as the new CEO of the company.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005122/en/
"I am grateful to have been selected as Riddle&Code's next CEO. We are an organisation led by a purpose – to onboard industrial machines to Web3. It is a privilege to lead a team dedicated to machine-driven token economies, enabling sustainable, green, resilient energy systems," said Calian. "That is the mission of our company. I will do my best to serve the team and our customers by enabling our leaders and people to do their best work."
This decision comes at a momentous time, as Riddle&Code evolves into a product-led service company specialising in Web3 infrastructure and establishing the unique RDDL Network blockchain, which provides the cornerstones for decentralised, secure, and trusted machine economies. Riddle&Code is preparing to be a key contributor to this network and aims to provide the best products, services, and solutions to make this vision flourish.
Working with enterprise partners such as Wien Energie, Daimler Mobility, Evonik, Litebit, and Telekom Innovation Laboratories (T-Labs), Riddle&Code has built an extensive portfolio of blockchain-powered software and hardware products across key industry segments, highlighted by renewable energy producers, electric vehicle manufacturers and large scale energy storage systems providers.
"We are at a natural turning point for the company, and John brings the leadership and expertise needed for Riddle&Code to enter this next phase. Our new purpose is to share our established knowledge and onboard as many industries as possible to Web3 to shape the future of interconnecting token economies with the RDDL Network. This goes way beyond the wildest ambitions of current token projects and energy tech companies." ~ Tom Fürstner, Founder and CTO of Riddle&Code.
The landscape for decentralised infrastructure is rapidly changing, and there has been an increase in demand for blockchain-based software systems due to the ongoing shift towards Web3. This new era requires industries to set up new operating and business models, combining old strengths with a new way of thinking.
Riddle&Code is now focused on being a key player in onboarding industries to Web3 and will provide specific products and services. Co-Founder and outgoing CEO Alexander Koppel will continue as Advisor to the CEO in the future and further support the company's mission. This announcement is the logical next step in the further evolution and continued progress of Riddle&Code and its subsidiary companies.
About Riddle&Code
Riddle&Code is a product-led services company specialising in onboarding industries to Web3. The company is the main driver for a world of interconnected token economies by enabling sustainable, green, and resilient machine industries. Riddle&Code offers various solutions to tailor industry-specific hardware wallets and an application suite to build on decentralised blockchains, mainly contributing to the RDDL Network blockchain protocol.
More information: www.riddleandcode.com
About the RDDL Network
The RDDL Network is a decentralised, industrial machine-powered blockchain protocol that uses a unique Proof-of Productivity (PoP) consensus mechanism that proves identity, data accuracy, and usage for all types of machines. It addresses infrastructure and standards as a whole and is designed to shape the future of interconnected token economies for the fourth industrial revolution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005122/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom